Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
BVF Partners specializes in fundamentally-driven investments in public and private biotechnology companies. It focuses on undervalued opportunities and long-term holdings in small-cap biotech firms[1][2][3][4][5].
The fund has a track record of investing in early-stage to late-stage biotech companies with a rigorous diligence process. Its portfolio includes notable names such as Syndax Pharmaceuticals, Revolution Medicines, Phathom Pharmaceuticals, Vividion Therapeutics, Prevail Therapeutics, Peloton Therapeutics, Relay Therapeutics and Akero Therapeutics[4]. As an investor rather than an operator or developer of drugs/therapies itself, it does not have its own clinical results or pipeline.
As of March 2025 filings:
The company actively partners with its portfolio firms but does not itself conduct R&D or hold proprietary therapeutic platforms.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on BVF Partners.